Published in J Biol Chem on July 09, 2004
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Mechanisms, regulation and consequences of protein SUMOylation. Biochem J (2010) 3.22
Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b. EMBO J (2006) 3.21
Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat Cell Biol (2005) 2.62
The multiple levels of regulation by p53 ubiquitination. Cell Death Differ (2010) 1.87
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
p53 regulation by ubiquitin. FEBS Lett (2011) 1.51
Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J Biol Chem (2009) 1.37
Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with perivascular retinal pigment epithelium atrophy. Am J Hum Genet (2007) 1.33
Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol (2008) 1.32
Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem (2009) 1.26
Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol (2005) 1.25
No Splicing, no dicing: non-proteolytic roles of the ubiquitin-proteasome system in transcription. J Biol Chem (2009) 1.14
Stimulation of in vitro sumoylation by Slx5-Slx8: evidence for a functional interaction with the SUMO pathway. DNA Repair (Amst) (2007) 1.14
E3 ubiquitin ligase activity of the trifunctional ARD1 (ADP-ribosylation factor domain protein 1). Proc Natl Acad Sci U S A (2005) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Regulation of the sumoylation system in gene expression. Curr Opin Cell Biol (2008) 1.09
Back to your heart: ubiquitin proteasome system-regulated signal transduction. J Mol Cell Cardiol (2011) 1.05
Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction. Physiol Rev (2014) 1.02
Ubiquitin proteolytic system: focus on SUMO. Expert Rev Proteomics (2008) 1.02
Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res (2008) 1.02
TOPORS, implicated in retinal degeneration, is a cilia-centrosomal protein. Hum Mol Genet (2010) 1.01
Meiosis in male Drosophila. Spermatogenesis (2012) 1.01
Genome stability roles of SUMO-targeted ubiquitin ligases. DNA Repair (Amst) (2009) 1.00
The substrates of Plk1, beyond the functions in mitosis. Protein Cell (2010) 0.97
Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology (2011) 0.96
SUMOylation of the small GTPase ARL-13 promotes ciliary targeting of sensory receptors. J Cell Biol (2012) 0.93
Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy. J Biol Chem (2010) 0.92
It takes two to tango: Ubiquitin and SUMO in the DNA damage response. Front Genet (2013) 0.90
Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains. J Biol Chem (2009) 0.90
Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev (2008) 0.90
Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy. Int J Nanomedicine (2011) 0.87
TRIMming p53 for ubiquitination. Proc Natl Acad Sci U S A (2009) 0.87
Role of E3 ubiquitin ligases in lung cancer. World J Clin Oncol (2013) 0.86
Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther (2010) 0.85
p28, a first in class peptide inhibitor of cop1 binding to p53. Br J Cancer (2013) 0.84
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis (2011) 0.84
It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. Genes Cancer (2012) 0.83
p53 Regulation Goes Live-Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling. Genes Cancer (2012) 0.81
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther (2016) 0.80
Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice. BMC Mol Biol (2010) 0.79
Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl (2011) 0.78
Mitotic Kinases and p53 Signaling. Biochem Res Int (2012) 0.78
Comprehensively surveying structure and function of RING domains from Drosophila melanogaster. PLoS One (2011) 0.78
UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier E3 ligase for zinc finger protein 131. J Biol Chem (2013) 0.77
Nuclear structure and chromosome segregation in Drosophila male meiosis depend on the ubiquitin ligase dTopors. Genetics (2011) 0.77
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination. Am J Hum Genet (2016) 0.77
Plk1 phosphorylation of Topors is involved in its degradation. Mol Biol Rep (2009) 0.76
Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491. Mol Oncol (2014) 0.75
TOPORS, a Dual E3 Ubiquitin and Sumo1 Ligase, Interacts with 26 S Protease Regulatory Subunit 4, Encoded by the PSMC1 Gene. PLoS One (2016) 0.75
Inhibition of PDGF-B induction and cell growth by syndecan-1 involves the ubiquitin and SUMO-1 ligase, Topors. PLoS One (2012) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
The role of autophagy in mitochondria maintenance: characterization of mitochondrial functions in autophagy-deficient S. cerevisiae strains. Autophagy (2007) 3.14
5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg Med Chem (2003) 3.13
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today (2006) 2.59
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Autophagy regulates ageing in C. elegans. Autophagy (2007) 2.22
Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J (2009) 2.14
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res (2009) 2.03
Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One (2008) 1.94
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A (2007) 1.92
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res (2007) 1.83
Epothilones: mechanism of action and biologic activity. J Clin Oncol (2004) 1.80
Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol Cell Biol (2006) 1.70
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res (2006) 1.59
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies. Exp Cell Res (2002) 1.47
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol (2003) 1.43
A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem (2006) 1.41
Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene (2003) 1.39
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res (2011) 1.32
A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J Biol Chem (2008) 1.31
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26
Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro. J Biol Chem (2006) 1.23
ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther (2008) 1.19
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell (2012) 1.19
The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A (2003) 1.18
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther (2011) 1.18
Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. J Biol Chem (2003) 1.17
DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem (2003) 1.15
G-quadruplexes induce apoptosis in tumor cells. Cancer Res (2006) 1.14
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1. J Biol Chem (2007) 1.13
Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem (2009) 1.11
Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One (2012) 1.09
Inactivation of Cdc13p triggers MEC1-dependent apoptotic signals in yeast. J Biol Chem (2003) 1.08
Nuclear translocation of cytochrome c during apoptosis. J Biol Chem (2004) 1.06
Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem (2003) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood) (2011) 1.03
TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J Proteome Res (2007) 1.02
Single-stranded DNA induces ataxia telangiectasia mutant (ATM)/p53-dependent DNA damage and apoptotic signals. J Biol Chem (2003) 1.01
Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res (2012) 1.01
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res (2006) 1.00
Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. Cancer Res (2006) 0.99
5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J Med Chem (2005) 0.97
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res (2003) 0.95
Tumorigenic potential of circulating prostate tumor cells. Oncotarget (2013) 0.94
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther (2002) 0.94
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res (2008) 0.93
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem (2003) 0.93
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res (2007) 0.93
Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. Bioorg Med Chem (2005) 0.92
Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. J Biol Chem (2011) 0.92
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol (2013) 0.91
A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS One (2011) 0.91
The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor. Oncogene (2004) 0.90
Interferon-β signaling contributes to Ras transformation. PLoS One (2011) 0.89
Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity. PLoS One (2012) 0.89
Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol. J Cell Biochem (2013) 0.88
Acidic pH induces topoisomerase II-mediated DNA damage. Proc Natl Acad Sci U S A (2003) 0.87
Macrocyclic hexaoxazoles: Influence of aminoalkyl substituents on RNA and DNA G-quadruplex stabilization and cytotoxicity. Bioorg Med Chem Lett (2010) 0.87
A G-quadruplex stabilizer induces M-phase cell cycle arrest. J Biol Chem (2009) 0.87
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res (2009) 0.86
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol (2005) 0.85
Protection of DNA ends by telomeric 3' G-tail sequences. J Biol Chem (2007) 0.85
Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers (2011) 0.85
Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activity. Biochemistry (2008) 0.84
Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem (2008) 0.83
Role of DNA topoisomerase IIbeta in neurite outgrowth. Brain Res (2007) 0.82
Ring-closing metathesis for the synthesis of a highly G-quadruplex selective macrocyclic hexaoxazole having enhanced cytotoxic potency. Bioorg Med Chem Lett (2008) 0.82
6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem (2006) 0.82
Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg Med Chem Lett (2002) 0.82
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs (2008) 0.82
Topoisomerase IIbeta is required for proper retinal development and survival of postmitotic cells. Biol Open (2014) 0.81
Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis. J Biol Chem (2013) 0.81
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer (2012) 0.81
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Invest New Drugs (2007) 0.80
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Am J Clin Oncol (2016) 0.80
Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. Bioorg Med Chem (2005) 0.80
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther (2011) 0.80
Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice. BMC Mol Biol (2010) 0.79
Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents. Bioorg Med Chem (2003) 0.79